Publications by authors named "Garcia-Samper Xochitl"
Genetic polymorphisms present in IL10, IL23R, NOD2, and ATG16L1 associated with susceptibility to inflammatory bowel disease in Mexican population.
Eur J Gastroenterol Hepatol
January 2020
Article Synopsis
- The study investigates the link between specific single nucleotide polymorphisms (SNPs) in immune system genes and inflammatory bowel disease (IBD) in a Mexican population, focusing on ulcerative colitis (UC) and Crohn's disease (CD).
- Key findings suggest that the AG genotype of the IL-10 SNP rs1800896 increases the risk for both UC and CD, while the AA genotype is protective; the T allele of another IL-10 SNP, rs3024505, is linked to UC onset and steroid treatment.
- Other SNPs (NOD2, IL23R, ATG16L1) showed no significant associations with IBD in the participants, underscoring the unique role of
HCV-Ag-specific TH17 cells secrete IL17, a cytokine involved in autoimmune diseases and regulated by IL10 and TGF-b. 5-12% of patients with chronic HCV infection have hypothyroidism. We evaluated the role of these cytokines in this patients by determining serum concentration of TsH, T3, free T4, IL2, IL10, IL12, IL17, TGF-b, anti-TG, TPO, CCP, GBM, and cardiolipin antibodies in 87 chronically noninterferon treated HCV-infected patients.
View Article and Find Full Text PDFIntroduction: Intestinal- and diffuse-type gastric adenocarcinomas differ in clinical outcome and genetic profile. Abnormal claudin expression has been well documented in several malignancies. Our aim was to find specific claudin markers for each type.
View Article and Find Full Text PDFBackground/aims: Thymalfasin has shown efficacy in the treatment of chronic HCV infection. The aim of this study was to evaluate the efficacy and tolerability of triple therapy with thymalfasin, peginterferon alpha-2a (PEG-IFN alpha-2a), and ribavirin in Hispanic patients with chronic viral hepatitis C who were nonresponders to prior treatment with interferon alfa (IFN-alpha)/ribavirin.
Methods: In this open-label study, 40 subjects received thymalfasin (1.